A retrospective analysis conducted by Tsao and colleagues [19] looked at the prognostic effects of p53 mutations or RAS mutations in a set of 450 patients with NSCLC who were randomized to observation or a platinum doublet in the adjuvant setting as part of the JBR10 study. This evidence concerns the gene TP53 and non-small cell lung carcinoma.